CXCL5 Modified Nanoparticle Surface Improves CXCR2
chemokine receptors
chemokines
immune cells
nanoparticles
surface chemistry
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
24 Dec 2019
24 Dec 2019
Historique:
received:
27
11
2019
revised:
17
12
2019
accepted:
24
12
2019
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
2
9
2020
Statut:
epublish
Résumé
Driving nanomaterials to specific cell populations is still a major challenge for different biomedical applications. Several strategies to improve cell binding and uptake have been tried thus far by intrinsic material modifications or decoration with active molecules onto their surface. In the present work, we covalently bound the chemokine CXCL5 on fluorescently labeled amino-functionalized SiO
Identifiants
pubmed: 31878341
pii: cells9010056
doi: 10.3390/cells9010056
pmc: PMC7016632
pii:
doi:
Substances chimiques
CXCL5 protein, human
0
Chemokine CXCL5
0
Receptors, Interleukin-8B
0
Silicon Dioxide
7631-86-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Materials (Basel). 2019 Jun 21;12(12):
pubmed: 31234290
J Vis Exp. 2014 Mar 28;(85):
pubmed: 24747480
Sci Technol Adv Mater. 2010 Feb 22;11(1):014101
pubmed: 27877316
Exp Dermatol. 2015 Apr;24(4):309-12
pubmed: 25690483
Nat Immunol. 2008 Sep;9(9):949-52
pubmed: 18711431
Nanoscale. 2012 Jan 21;4(2):486-95
pubmed: 22095171
Cancer Cell Int. 2018 May 2;18:68
pubmed: 29743818
Immunol Invest. 1992 Oct;21(6):589-96
pubmed: 1428026
Nat Commun. 2019 Sep 27;10(1):4404
pubmed: 31562303
J Neurovirol. 2006 Jun;12(3):211-8
pubmed: 16877302
Sci Rep. 2015 Dec 01;5:17040
pubmed: 26621190
Chimia (Aarau). 2016 Dec 21;70(12):856-859
pubmed: 28661356
Biomaterials. 2012 Feb;33(4):1180-9
pubmed: 22056754
Adv Drug Deliv Rev. 2019 Apr;144:57-77
pubmed: 31400350
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Exp Ther Med. 2013 Mar;5(3):987-991
pubmed: 23407636
Bioeng Transl Med. 2016 Jun 20;1(1):47-62
pubmed: 29313006
Genes Cells. 2013 Jan;18(1):1-16
pubmed: 23145839
Nature. 1998 Apr 9;392(6676):565-8
pubmed: 9560152
Biomaterials. 2010 Sep;31(25):6555-66
pubmed: 20537383
Pharmaceutics. 2019 Jan 15;11(1):
pubmed: 30650541
Langmuir. 2008 Aug 19;24(16):8964-70
pubmed: 18590302
Eur J Immunol. 2001 Nov;31(11):3291-7
pubmed: 11745346
J Control Release. 2014 Sep 28;190:485-99
pubmed: 24984011
Cell Death Dis. 2019 Feb 21;10(3):178
pubmed: 30792394
Int J Nanomedicine. 2018 Jul 27;13:4379-4389
pubmed: 30100721
FEBS Lett. 2003 May 8;542(1-3):79-83
pubmed: 12729902
Hum Immunol. 2018 Nov;79(11):809-816
pubmed: 30125599
J Med Chem. 2017 Jun 22;60(12):4735-4779
pubmed: 28165741
J Physiol Biochem. 2018 May;74(2):313-324
pubmed: 29526026
Trends Immunol. 2017 Dec;38(12):927-941
pubmed: 28935522
Int J Mol Sci. 2017 Oct 02;18(10):
pubmed: 28974038
Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2481-2484
pubmed: 30255816
ACS Appl Mater Interfaces. 2013 Dec 26;5(24):13171-9
pubmed: 24245615
Pharmacol Rev. 2013 Nov 11;66(1):1-79
pubmed: 24218476
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
Prog Mol Biol Transl Sci. 2013;118:205-22
pubmed: 23764055
Int J Immunopharmacol. 1995 Feb;17(2):103-8
pubmed: 7657403